Intellia Therapeutics, Inc. (NTLA) Stock Analysis and Metrics

Sector: Healthcare Industry: Biotechnology CIK: 0001652130

Market Cap 1.26 Bn

P/E -3.05

P/S 18.66

Div. Yield 0.00

Add ratio to table...

About

Intellia Therapeutics, Inc., a clinical-stage gene editing company, is at the forefront of developing potentially curative genome editing treatments using CRISPR/Cas9-based technologies. The company's primary business activities involve developing gene editing therapies for various diseases, including genetic liver diseases, hereditary angioedema, and alpha-1 antitrypsin deficiency. Intellia's main business activities are centered on gene editing therapies, with a particular focus on in vivo research programs. The company's lead in vivo candidates,...

Intellia Therapeutics, Inc., a clinical-stage gene editing company, is at the forefront of developing potentially curative genome editing treatments using CRISPR/Cas9-based technologies. The company's primary business activities involve developing gene editing therapies for various diseases, including genetic liver diseases, hereditary angioedema, and alpha-1 antitrypsin deficiency.

Intellia's main business activities are centered on gene editing therapies, with a particular focus on in vivo research programs. The company's lead in vivo candidates, NTLA-2001 and NTLA-2002, are the first CRISPR/Cas9-based therapy candidates to be administered systemically for precision editing of a gene in a target tissue in humans. NTLA-2001 is being developed for the treatment of transthyretin (ATTR) amyloidosis, a progressive and fatal disorder resulting from deposition of insoluble amyloid fibrils into multiple organs and tissues. Intellia is currently enrolling patients in a global, pivotal Phase 3 MAGNITUDE trial to evaluate the efficacy and safety of NTLA-2001 in adults with ATTR-CM. NTLA-2002 is being developed for the treatment of hereditary angioedema (HAE), a rare genetic disease characterized by severe, recurring, and unpredictable inflammatory attacks in various organs and tissues. The company has completed enrollment and dosing in the Phase 2 portion of the Phase 1/2 study and plans to initiate a global pivotal Phase 3 study in the second half of 2024.

Intellia's revenue is generated through the development and commercialization of its gene editing therapies. The company's leadership position in the field of genome editing is driven by its broad and deep gene editing toolbox, which enables it to select the best tools for each therapeutic application.

The biotechnology and pharmaceutical industries are highly competitive, and Intellia faces competition from companies that use genome editing or gene therapy development platforms and from companies focused on more traditional therapeutic modalities such as small molecules and antibodies. Intellia's competitors include Alnylam Pharmaceuticals, AstraZeneca Pharmaceuticals LP, BridgeBio Pharma Inc., Ionis Pharmaceuticals, Inc., Metagenomi Technologies, LLC, Novo Nordisk A/S, and Pfizer, Inc.

Intellia has formed several collaborations and partnerships to accelerate the development and commercialization of CRISPR/Cas9-based products. These collaborations include Regeneron Pharmaceuticals, Inc., AvenCell Therapeutics, Inc., SparingVision SAS, Kyverna Therapeutics, Inc., ONK Therapeutics, Ltd, and Rewrite Therapeutics Inc.

Intellia believes it is well-positioned in terms of its intellectual property due to its broad worldwide portfolio of IP, including patents and patent applications, in areas relevant to the development and commercialization of human therapeutic products using CRISPR/Cas9 technology. The company protects its IP by maintaining trade secrets relating to its proprietary technology innovations and know-how and intends to take additional steps, where appropriate, to further protect its IP rights.

As a biopharmaceutical company, Intellia is subject to extensive legal and regulatory requirements. The company needs approval from regulatory agencies for its clinical studies, development, manufacturing, distribution, exportation and importation, commercialization, marketing, and reimbursement relating to its products and product candidates. Relevant regulatory authorities include the FDA, the EMA, the EC, EU Member State agencies, and other countries' similar agencies.

In vivo gene therapy products, including genetically modified cells, that lead to a durable modification of cells or tissues may meet the definition of a regenerative medicine therapy. Intellia's products are subject to regulation under the Food, Drug and Cosmetic Act and the Public Health Service Act and other federal, state, local, and foreign statutes and regulations.

Intellia's allogeneic platform is designed to overcome one of the key challenges to current allogeneic approaches, which is host rejection of the adoptive cell therapy. In preclinical studies, Intellia's allogeneic technology demonstrated the ability to create T cells with high anti-tumor activity capable of avoiding host T and NK cells, and thereby persisting to maintain durable responses.

In addition to its lead in vivo candidates, Intellia is advancing multiple ex vivo programs, including engineered cell therapies for immuno-oncology and autoimmune diseases. The company is leveraging its proprietary allogeneic cell engineering platform to develop allogeneic cellular therapies that can be used to treat both oncological and immunological diseases.

Intellia's manufacturing strategy involves entering into certain manufacturing and supply arrangements with third-party suppliers to support production of its product candidates and their components. The company plans to continue to rely on qualified third-party organizations and its own capabilities to produce or process bulk compounds, formulated compounds, viral vectors, or engineered cells for IND-supporting activities and to supply materials for clinical trials.

Investment thesis

Bull case

Intellia’s one‑time gene‑editing platform remains uniquely positioned to transform a series of orphan diseases that traditionally require chronic, high‑cost therapies. The ATTRv‑PN program, now cleared by the FDA to resume enrollment, is poised to generate early revenue streams through a first‑in‑class treatment that offers durable disease modification with a single infusion. The timing of the regulatory lift aligns with the company’s cash runway, allowing it to sustain operations through the anticipated data readout in the second half of 2026 and to prepare for a commercial launch in the first half of 2027. The company’s balanced capital structure, with roughly $670 million in cash and a readily available ATM facility, underpins this aggressive pipeline strategy and gives it breathing room to absorb the cost of the ongoing ATTR‑CM hold without immediate liquidity pressure.
The company’s focus on the ATTR‑CM indication, despite the current hold, offers a far larger commercial opportunity than the ATTRv‑PN program alone. While the heart‑related form of amyloidosis has a more aggressive disease trajectory and a higher unmet need, the potential market size is considerably larger, encompassing a broader patient population that is already underserved by existing therapies. Intellia’s data indicating a less than 1% incidence of Grade 4 liver enzyme elevations among over 650 patients provides a reassuring safety signal that may be persuasive to regulators once a robust mitigation plan is articulated. The company’s proactive engagement with the FDA, as evidenced by the clinical hold, demonstrates a willingness to cooperate and adapt, which could translate into a favorable risk–benefit assessment if the hold is lifted.
Lonvo‑z, the one‑time treatment for hereditary angioedema, has already completed enrollment and is on track to deliver topline results in mid‑2026. The therapeutic benefit of completely eliminating attacks would be a paradigm shift for a patient group that currently relies on episodic, costly therapies. With the company’s extensive experience in the ATTR platform, the manufacturing scale‑up and supply chain logistics for Lonvo‑z can likely be leveraged, reducing time‑to‑market costs. The company’s recent collaboration revenue increase, driven primarily by a partnership with a major biopharma, underscores its capacity to monetize data assets and potentially secure additional licensing revenue.
Intellia’s choice of a lipid‑nanoparticle (LNP) delivery system that is common across both nex‑z and lonvo‑z indicates an opportunity for platform synergies. By reusing the same delivery vehicle, the company can potentially lower manufacturing complexity and reduce regulatory hurdles associated with novel delivery components. This consolidation can translate into cost efficiencies, improving gross margins once the drugs enter the commercial phase. Moreover, the shared LNP platform may enable cross‑indication data sharing, which could accelerate the development timeline for future programs targeting other monogenic diseases.
The company's emphasis on the high mortality of ATTR amyloidosis signals a robust market narrative that resonates with payers and clinicians alike. By framing the therapy as a life‑extending intervention, Intellia aligns its value proposition with reimbursement models that prioritize durable outcomes over incremental symptom control. This positioning is likely to strengthen payer negotiations, especially in markets where chronic therapies are heavily scrutinized for cost effectiveness. The narrative also enhances investor confidence, as it underscores a clear differentiation from existing treatments that merely slow disease progression.

Intellia’s one‑time gene‑editing platform remains uniquely positioned to transform a series of orphan diseases that traditionally require chronic, high‑cost therapies. The ATTRv‑PN program, now cleared by the FDA to resume enrollment, is poised to generate early revenue streams through a first‑in‑class treatment that offers durable disease modification with a single infusion. The timing of the regulatory lift aligns with the company’s cash runway, allowing it to sustain operations through the anticipated data readout in the second half of 2026 and to prepare for a commercial launch in the first half of 2027. The company’s balanced capital structure, with roughly $670 million in cash and a readily available ATM facility, underpins this aggressive pipeline strategy and gives it breathing room to absorb the cost of the ongoing ATTR‑CM hold without immediate liquidity pressure.
The company’s focus on the ATTR‑CM indication, despite the current hold, offers a far larger commercial opportunity than the ATTRv‑PN program alone. While the heart‑related form of amyloidosis has a more aggressive disease trajectory and a higher unmet need, the potential market size is considerably larger, encompassing a broader patient population that is already underserved by existing therapies. Intellia’s data indicating a less than 1% incidence of Grade 4 liver enzyme elevations among over 650 patients provides a reassuring safety signal that may be persuasive to regulators once a robust mitigation plan is articulated. The company’s proactive engagement with the FDA, as evidenced by the clinical hold, demonstrates a willingness to cooperate and adapt, which could translate into a favorable risk–benefit assessment if the hold is lifted.
Lonvo‑z, the one‑time treatment for hereditary angioedema, has already completed enrollment and is on track to deliver topline results in mid‑2026. The therapeutic benefit of completely eliminating attacks would be a paradigm shift for a patient group that currently relies on episodic, costly therapies. With the company’s extensive experience in the ATTR platform, the manufacturing scale‑up and supply chain logistics for Lonvo‑z can likely be leveraged, reducing time‑to‑market costs. The company’s recent collaboration revenue increase, driven primarily by a partnership with a major biopharma, underscores its capacity to monetize data assets and potentially secure additional licensing revenue.
Intellia’s choice of a lipid‑nanoparticle (LNP) delivery system that is common across both nex‑z and lonvo‑z indicates an opportunity for platform synergies. By reusing the same delivery vehicle, the company can potentially lower manufacturing complexity and reduce regulatory hurdles associated with novel delivery components. This consolidation can translate into cost efficiencies, improving gross margins once the drugs enter the commercial phase. Moreover, the shared LNP platform may enable cross‑indication data sharing, which could accelerate the development timeline for future programs targeting other monogenic diseases.
The company's emphasis on the high mortality of ATTR amyloidosis signals a robust market narrative that resonates with payers and clinicians alike. By framing the therapy as a life‑extending intervention, Intellia aligns its value proposition with reimbursement models that prioritize durable outcomes over incremental symptom control. This positioning is likely to strengthen payer negotiations, especially in markets where chronic therapies are heavily scrutinized for cost effectiveness. The narrative also enhances investor confidence, as it underscores a clear differentiation from existing treatments that merely slow disease progression.

Bear case

The fatal liver event in the ATTR‑CM trial, coupled with the subsequent FDA clinical hold, raises a significant safety red flag that could erode confidence among regulators, clinicians, and payers. Even though the incidence of Grade 4 liver enzyme elevations is less than 1% in a large cohort, the severity of the event and the lack of a definitive causal link to the therapy may trigger extended scrutiny and more stringent post‑market surveillance requirements. The company’s evasive answers regarding comorbidities and potential causative factors may suggest insufficient data transparency, further unsettling stakeholders.
The persistence of the hold on the ATTR‑CM program, while the ATTRv‑PN trial proceeds, creates a discontinuity in the company’s pipeline that can dilute investor expectations. The ATTR‑CM indication, representing a larger market, remains in regulatory limbo, potentially postponing a substantial revenue stream that could have justified the company’s valuation. The uncertainty surrounding a viable mitigation plan increases the probability of a protracted hold or even a partial or full withdrawal from the market.
The company’s ability to recover from the hold is heavily dependent on the outcome of the comprehensive safety analysis, which is currently inconclusive. The risk that the FDA may demand additional pre‑clinical studies, or impose stringent post‑approval monitoring requirements, could increase development costs and delay commercial launch. In the worst case, regulatory action could compel the company to halt the ATTR‑CM program entirely, leading to a loss of investment and potential reputational damage.
Intellia’s cash runway, while sufficient until mid‑2027, is subject to the unpredictability of the ATTR‑CM hold and the time needed to complete additional trials or remedial actions. The company’s financial statements show a decline in R&D expenses but still record substantial operational costs that could be exacerbated by the hold. If the company cannot secure additional financing or partnerships, it may be forced to cut back on other pipeline programs, limiting future growth opportunities.
The competitive landscape for ATTR amyloidosis is intensifying, with multiple players already offering or developing therapies that target the same patient populations. Alnylam’s injectable Amvuttra, Pfizer’s Vyndaqel, and BridgeBio’s Attruby represent significant market entrants with established clinical data, marketing pipelines, and payer relationships. Intellia’s potential delay in launching ATTR‑CM may allow competitors to capture market share, diminishing the commercial viability of its therapy.

The fatal liver event in the ATTR‑CM trial, coupled with the subsequent FDA clinical hold, raises a significant safety red flag that could erode confidence among regulators, clinicians, and payers. Even though the incidence of Grade 4 liver enzyme elevations is less than 1% in a large cohort, the severity of the event and the lack of a definitive causal link to the therapy may trigger extended scrutiny and more stringent post‑market surveillance requirements. The company’s evasive answers regarding comorbidities and potential causative factors may suggest insufficient data transparency, further unsettling stakeholders.
The persistence of the hold on the ATTR‑CM program, while the ATTRv‑PN trial proceeds, creates a discontinuity in the company’s pipeline that can dilute investor expectations. The ATTR‑CM indication, representing a larger market, remains in regulatory limbo, potentially postponing a substantial revenue stream that could have justified the company’s valuation. The uncertainty surrounding a viable mitigation plan increases the probability of a protracted hold or even a partial or full withdrawal from the market.
The company’s ability to recover from the hold is heavily dependent on the outcome of the comprehensive safety analysis, which is currently inconclusive. The risk that the FDA may demand additional pre‑clinical studies, or impose stringent post‑approval monitoring requirements, could increase development costs and delay commercial launch. In the worst case, regulatory action could compel the company to halt the ATTR‑CM program entirely, leading to a loss of investment and potential reputational damage.
Intellia’s cash runway, while sufficient until mid‑2027, is subject to the unpredictability of the ATTR‑CM hold and the time needed to complete additional trials or remedial actions. The company’s financial statements show a decline in R&D expenses but still record substantial operational costs that could be exacerbated by the hold. If the company cannot secure additional financing or partnerships, it may be forced to cut back on other pipeline programs, limiting future growth opportunities.
The competitive landscape for ATTR amyloidosis is intensifying, with multiple players already offering or developing therapies that target the same patient populations. Alnylam’s injectable Amvuttra, Pfizer’s Vyndaqel, and BridgeBio’s Attruby represent significant market entrants with established clinical data, marketing pipelines, and payer relationships. Intellia’s potential delay in launching ATTR‑CM may allow competitors to capture market share, diminishing the commercial viability of its therapy.

Consolidation Items Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	113.30 Bn	28.64	9.44	-
2	REGN	Regeneron Pharmaceuticals, Inc.	78.40 Bn	17.37	5.47	1.99 Bn
3	ALNY	Alnylam Pharmaceuticals, Inc.	41.41 Bn	150.53	13.15	-
4	MESO	Mesoblast Ltd	21.68 Bn	-169.86	1,260.73	0.12 Bn
5	RPRX	Royalty Pharma plc	19.93 Bn	25.90	8.38	8.95 Bn
6	ZLAB	Zai Lab Ltd	19.57 Bn	-111.69	80.73	0.20 Bn
7	MRNA	Moderna, Inc.	18.75 Bn	-6.63	9.65	0.59 Bn
8	ROIV	Roivant Sciences Ltd.	18.40 Bn	-30.01	3,205.68	-

Research Tools

Intellia Therapeutics, Inc. (NASDAQ: NTLA)

About

Investment thesis

Bull case

Bear case

Consolidation Items Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Research Tools

Intellia Therapeutics, Inc. (NASDAQ: NTLA)

About

Investment thesis

Bull case

Bear case

Consolidation Items Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password